Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)

用于治疗疼痛的计算机化化学感应眼眶额网络训练 (CBOT-P) 的开发和评估

基本信息

  • 批准号:
    10547925
  • 负责人:
  • 金额:
    $ 50万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-20 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

PHASE I/II (FAST/TRACK) ABSTRACT The Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P) is a project to develop an effective, scalable, user-friendly, and home- based neuromodulatory platform for broad-spectrum treatment of chronic pain conditions with associated negative affect and cognitive impairments. Chronic pain (CP) affects 1.5 billion people globally, and causes severe human suffering, disability, and high financial burden. Clinical and neuroscience studies show that CP over time leads to shrinkage in the prefrontal cortex (PFC) regions and their deep brain connections critical to emotion, motivation, and cognitive functions. As a result, more than 40% of CP patients suffer negative affect (i.e., anxiety and depression), cognitive and decision-making problems and reduced drive. Chronic pain with negative affect (CP-N) is more debilitating, harder to treat, costlier to payers and significantly more associated with opioid use, overdose, and deaths. In a stakeholder value canvassing exercise CP sufferers and pain doctors unanimously desire new non-invasive, home-based, safe, and effective interventions that can reduce pain severity by more than 10%, suggesting that current treatments have limitations. Anterograde and retrograde anatomical tracings have been used to demonstrate direct (monosynaptic) anatomical connection between the OFC and the descending inhibitory pain nodes at the midbrain periaqueductal gray matter (PAG). Transition to CP is marked by weakened modulation of the PAG-descending inhibition. Evon Medics, a small business specializing in olfactory neurotherapeutics, developed an innovative chemosensory-based orbitofrontal cortex (OFC) stimulation device, called CBOT-P, for home use, to increase OFC plasticity and effect OFC-induced regulation of pain and negative affect. We now plan to refine this product for broad pain conditions and quickly make it available to the population. OFC is the part of the prefrontal cortex that plays key roles in multisensory integration, affect regulation, and decision-making. The lateral OFC, which is consistently activated by pain, is connected to other cortical brain regions that process pain; and the medial OFC, which networks with medial temporal affect networks, is engaged by mindfulness therapy for pain and plays important role in positive affect and drive. Unfortunately, CP and opioid analgesics are associated with OFC shrinkage, which amplifies pain through increased negative affect (NA) and cognitive impairment. The success of CBOT-P in acute relief of NA and pain in our pilot studies is not surprising because single-pulsed electrical stimulations with OFC-placed electrodes acutely relieved NA in humans in invasive deep brain stimulation, and experimentally induced stimulation of the OFC in animal models and humans activates the PAG to reduce pain sensitization. The CBOT-P uses Evon’s proprietary regimen of 10 odorant phytochemicals to stimulate the secondary olfactory cortex (i.e. the OFC) repetitively, with established micro-controller- regulated stimulation parameter settings that maintain persistent activation of the OFC and medial temporal regions, without habituation; paired with digitally-administered olfactory psychophysical training tasks that activate same regions, for synergistic effect on long-term neuroplasticity changes that prevents CP-induced shrinkage. As a second mechanism of action, the olfactory stimulants were fortified with proprietary components, such as beta-caryophyllene (BCP), a selective endocannabinoid-2 receptor agonist, which has strong anti-inflammatory and antinociceptive effects, and scalable for acute positive affect. In the Phase I of this Fast-Track SBIR application, we will (a) configure CBOT-P regimen and stimulation parameters for faster onset of mood elevating and analgesic effects, focusing on Chronic Low Back Pain populations and (b) establish its neural mechanism of action through target-engagement studies of OFC activity and functional connectivity with other pain regulating regions at baseline. In Phase II, we will perform a powered randomized trial of the refined CBOT-P from Phase I, compared to sham CBOT in CLBP, to determine its short- and long-term effectiveness on Pain, Affect, Cognition and cortical brain Structure (PACS), long-term safety, and indications. We will also collect user experiences to help refine a final marketable CBOT product, enter the FDA breakthrough designation program for pain that would lead to Medicare/Medicaid reimbursement, engage a wider network of pain stakeholders, and establish marketing for commercial success. Project success will be enhanced through strong collaborations between Evon Medics, Johns Hopkins (JHU) Pain Center, Howard University investigators, community pain providers and collaborating manufacturers. To the best of our knowledge this will be the first home-based combinatorial digital- chemosensory neuromodulatory product for stimulation of deep brain regions for CP management.
阶段I/II(快速/跟踪)摘要 基于计算机化学传感的眼眶前额网络的发展与评价 疼痛治疗培训(CBOT-P)是一个旨在开发有效、可扩展、用户友好和家庭- 基于神经调节平台的慢性疼痛的广谱治疗 消极情绪和认知障碍。慢性疼痛(CP)影响着全球15亿人,并导致 严重的人类痛苦、残疾和沉重的经济负担。临床和神经科学研究表明,CP 随着时间的推移,会导致前额叶皮质(PFC)区域及其深部大脑连接的萎缩,这些连接对 情绪、动机和认知功能。因此,超过40%的慢性阻塞性肺病患者受到负面影响 (例如,焦虑和抑郁)、认知和决策问题以及动力减弱。慢性疼痛伴 负面情绪(CP-N)更令人虚弱,更难治疗,对支付者来说代价更高,而且明显更具关联性 阿片类药物的使用,服药过量,以及死亡。在利益相关者价值拉票活动中,CP患者和痛苦 医生们一致希望新的非侵入性、基于家庭的、安全和有效的干预措施可以减少 疼痛严重程度降低了10%以上,这表明目前的治疗方法有局限性。顺行和 逆行解剖示踪已被用来证明直接(单突触)解剖联系 位于中脑导水管周围灰质(PAG)的OFC和下行抑制性痛结之间。 向CP的转变以PAG下行抑制的调制减弱为标志。埃文医护人员,一个小的 企业专门从事嗅觉神经疗法,开发了一种创新的基于化学传感的 眼眶额叶皮质(OFC)刺激装置,称为CBOT-P,家用,以增加OFC可塑性和 FC诱导的疼痛调节和负性情绪的影响。我们现在计划提炼这款产品以适应广泛的疼痛 并迅速将其提供给民众。OFC是前额叶皮质中起作用的部分 在多感官整合、影响调节和决策中的关键作用。横向OFC,这是 持续地被疼痛激活,连接到处理疼痛的大脑其他皮质区域;内侧 OFC与内侧颞叶影响网络建立网络,从事正念疗法治疗疼痛和 在积极的情感和动力方面起着重要的作用。不幸的是,CP和阿片类镇痛剂与 OFC萎缩,它通过增加负面情绪(NA)和认知障碍来放大疼痛。这个 在我们的先导研究中,CBOT-P在急性缓解NA和疼痛方面的成功并不令人惊讶,因为单脉冲 OFC电极电刺激对人侵袭性脑深部NA的强烈缓解作用 刺激,并在动物模型和人类实验中诱导刺激OFC激活 PAG可降低疼痛敏感度。CBOT-P使用Evon的10种气味植物化学物质的专有方案 利用已建立的微控制器,重复刺激次级嗅觉皮质(即OFC)- 可持续激活OFC和内侧颞叶的调节刺激参数设置 没有习惯化的区域;与数字管理的嗅觉心理物理训练任务配对 激活相同的区域,对防止CP诱导的长期神经可塑性变化产生协同效应 缩水。作为第二种作用机制,嗅觉刺激剂得到了专利的强化 成分,如β-石竹烯(BCP),一种选择性内源性大麻-2受体激动剂,具有 强烈的抗炎和抗伤害作用,并可扩展为急性积极影响。 在此Fast-Track SBIR应用程序的第一阶段中,我们将(A)配置CBOT-P方案和 刺激参数可加快情绪起效和止痛效果,侧重于慢性腰背部 (B)通过OFC的靶点接触研究,建立其神经作用机制 基线时与其他疼痛调节区域的活动和功能连接。在第二阶段,我们将执行一项 一期精制CBOT-P与CLBP中假CBOT的动力性随机试验 确定其对疼痛、情感、认知和大脑皮质结构(PAC)的短期和长期有效性, 长期安全性和适应症。我们还将收集用户体验,以帮助完善最终的适销对路CBOT 产品,进入FDA突破性疼痛指定计划,这将导致联邦医疗保险/医疗补助 报销,吸引更广泛的疼痛利益相关者网络,并建立商业营销 成功。项目的成功将通过Evon医务人员和Johns之间的强大合作而得到加强 霍普金斯疼痛中心、霍华德大学研究人员、社区疼痛提供者和协作 制造商。据我们所知,这将是第一个基于家庭的组合数字- 化学感受性神经调节产品,用于刺激脑深部区域进行脑性瘫痪治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Charles Chiedu Nwaokobia其他文献

Charles Chiedu Nwaokobia的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Charles Chiedu Nwaokobia', 18)}}的其他基金

Development and Evaluation of Portable Compendium of Psychophysical and Physiological Tests for Alzheimer's Disease and Related Dementias (ADRD)
阿尔茨海默病和相关痴呆症(ADRD)便携式心理物理和生理测试纲要的开发和评估
  • 批准号:
    10699349
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)
用于药物使用障碍远程管理的增强型数字化学感应嗅觉训练的开发和评估(编辑)
  • 批准号:
    10794665
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)
用于药物使用障碍远程管理的增强型数字化学感应嗅觉训练的开发和评估(编辑)
  • 批准号:
    10741580
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)
用于药物使用障碍远程管理的增强型数字化学感应嗅觉训练的开发和评估(编辑)
  • 批准号:
    10469912
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease (AD)
针对早期阿尔茨海默病 (AD) 认知衰退的计算机嗅觉训练计划 (COT) 的开发和评估
  • 批准号:
    10574428
  • 财政年份:
    2018
  • 资助金额:
    $ 50万
  • 项目类别:
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease
针对早期阿尔茨海默病认知衰退的计算机嗅觉训练计划 (COT) 的开发和评估
  • 批准号:
    10614897
  • 财政年份:
    2018
  • 资助金额:
    $ 50万
  • 项目类别:
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease (AD)
针对早期阿尔茨海默病 (AD) 认知衰退的计算机嗅觉训练计划 (COT) 的开发和评估
  • 批准号:
    10399659
  • 财政年份:
    2018
  • 资助金额:
    $ 50万
  • 项目类别:
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease (AD)
针对早期阿尔茨海默病 (AD) 认知衰退的计算机嗅觉训练计划 (COT) 的开发和评估
  • 批准号:
    10256329
  • 财政年份:
    2018
  • 资助金额:
    $ 50万
  • 项目类别:

相似海外基金

Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
  • 批准号:
    10778757
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
Selective actin remodeling of sensory neurons for acute pain management
感觉神经元的选择性肌动蛋白重塑用于急性疼痛管理
  • 批准号:
    10603436
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
  • 批准号:
    10783106
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
Development of A Focused Ultrasound Device for Noninvasive, Peripheral Nerve Blockade to Manage Acute Pain
开发用于非侵入性周围神经阻断来治疗急性疼痛的聚焦超声装置
  • 批准号:
    10740796
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
Predicting Pediatric Sickle Cell Disease Acute Pain Using Mathematical Models Based on mHealth Data
使用基于移动健康数据的数学模型预测儿童镰状细胞病急性疼痛
  • 批准号:
    10599401
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
Non-Contingent Acute Pain Stress Drives Analgesic Protection in Rats.
非偶然急性疼痛应激驱动大鼠镇痛保护。
  • 批准号:
    575854-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Prefrontal Cortex Hemodynamic Responses to Mindfulness Meditation and Acute Pain
前额皮质血流动力学对正念冥想和急性疼痛的反应
  • 批准号:
    467076
  • 财政年份:
    2021
  • 资助金额:
    $ 50万
  • 项目类别:
    Studentship Programs
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
  • 批准号:
    9979265
  • 财政年份:
    2020
  • 资助金额:
    $ 50万
  • 项目类别:
Endocannabinoid Metabolism in Acute Pain
急性疼痛中的内源性大麻素代谢
  • 批准号:
    10356880
  • 财政年份:
    2020
  • 资助金额:
    $ 50万
  • 项目类别:
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
  • 批准号:
    10218273
  • 财政年份:
    2020
  • 资助金额:
    $ 50万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了